

Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

HER2/ErbB2 (29D8) Rabbit mAb

RRID:AB_10692490

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2165, RRID:AB_10692490

Antibody Information

URL: http://antibodyregistry.org/AB_10692490

Proper Citation: Cell Signaling Technology Cat# 2165, RRID:AB_10692490

Target Antigen: HER2/ErbB2 (29D8) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IHC-F, IF-IC, F. Consolidation on 11/2018: AB_10692490, AB_10831814, AB_560966.

Antibody Name: HER2/ErbB2 (29D8) Rabbit mAb

Description: This monoclonal targets HER2/ErbB2 (29D8) Rabbit mAb

Target Organism: rat, h, m, mouse, r, human

Antibody ID: AB_10692490

Vendor: Cell Signaling Technology

Catalog Number: 2165

Record Creation Time: 20250820T060157+0000

Record Last Update: 20250820T230724+0000

Ratings and Alerts

No rating or validation information has been found for HER2/ErbB2 (29D8) Rabbit mAb.

No alerts have been found for HER2/ErbB2 (29D8) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 56 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Cheng X, et al. (2026) Interleukin-34-Induced Arg1+ Macrophages Play a Key Role in Breast Cancer Brain Metastasis. *Cancer research communications*, 6(6), 1388.

Rampa DR, et al. (2026) Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1454.

Burke CM, et al. (2026) Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. *Molecular cancer therapeutics*, 25(1), 156.

Kang M, et al. (2026) Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. *Molecular cancer therapeutics*, 25(5), 814.

Rao X, et al. (2026) Paired patient-derived organoids reveal transcription factor-driven epigenetic remodeling in breast cancer metastasis. *Cell stem cell*, 33(4), 622.

Ma K, et al. (2026) ErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging. *Cell*, 189(11), 3413.

Lam D, et al. (2026) Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function. *Cancers*, 18(3).

Garg SK, et al. (2026) Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier. *Cell reports*, 45(3), 117050.

Fu Z, et al. (2026) Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer. *Cancer cell*.

Theardy MS, et al. (2025) Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. *Cell reports. Medicine*, 6(8), 102253.

Conticelli D, et al. (2025) AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer. *Cancer research*, 85(16), 3111.

Liao CY, et al. (2025) CD3xHER2 bsAb-Mediated Activation of Resting T-cells at HER2 Positive Tumor Clusters Is Sufficient to Trigger Bystander Eradication of Distant HER2 Negative Clusters Through IFN γ and TNF α . *European journal of immunology*, 55(4), e202451589.

Abdulkareem NM, et al. (2025) Interactions between ADGRF1 (GPR110) and extracellular matrix proteins govern its effects on tumorigenesis in HER2-positive breast cancer. *British journal of pharmacology*, 182(11), 2524.

Pataccini G, et al. (2025) Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country. *Scientific reports*, 15(1), 2415.

Xia Z, et al. (2025) circADAMTS12 Inhibits the Antitumor Activity of Microglia to Enable Metastatic Colonization in the Brain. *Cancer research*, 85(24), 4977.

Deng T, et al. (2025) CINTER-seq: Chemical profiling reveals interaction-dependent cell landscapes and gene signatures in vivo. *Immunity*, 58(9), 2336.

Chen W, et al. (2025) Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding. *Cancer discovery*.

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. *NPJ breast cancer*, 11(1), 135.

Trekitkarnmongkol W, et al. (2024) Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer. *British journal of cancer*, 131(1), 171.

Mucciolo G, et al. (2024) EGFR-activated myofibroblasts promote metastasis of pancreatic cancer. *Cancer cell*, 42(1), 101.